Meta-analysis of 104 trials (10 353 patients) of CD3-based T cell-engaging bispecific antibodies: grade ≥3 treatment-related adverse events 70·3% in haematological cancers vs 45·3% in solid tumours; cytokine release syndrome most common; 1·0% treatment-related deaths.
Meta-analysisn = 10,353
Zhu et al. Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials